12/24
09:23 am
ntla
Here's Why We're Watching Intellia Therapeutics' (NASDAQ:NTLA) Cash Burn Situation [Yahoo! Finance]
Low
Report
Here's Why We're Watching Intellia Therapeutics' (NASDAQ:NTLA) Cash Burn Situation [Yahoo! Finance]
12/3
04:01 pm
ntla
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
11/25
07:40 am
ntla
Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy [Yahoo! Finance]
Low
Report
Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy [Yahoo! Finance]
11/25
07:30 am
ntla
Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy
Low
Report
Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy
11/22
08:42 am
ntla
Down 33% in 1 Month, Should You Buy the Dip With Intellia Therapeutics Stock? [Yahoo! Finance]
Low
Report
Down 33% in 1 Month, Should You Buy the Dip With Intellia Therapeutics Stock? [Yahoo! Finance]
11/19
05:42 pm
ntla
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $90.00 price target on the stock.
Medium
Report
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $90.00 price target on the stock.
11/18
01:35 pm
ntla
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its price target lowered by analysts at Wells Fargo & Company from $80.00 to $70.00. They now have an "overweight" rating on the stock.
Low
Report
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its price target lowered by analysts at Wells Fargo & Company from $80.00 to $70.00. They now have an "overweight" rating on the stock.
11/18
11:36 am
ntla
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $14.00 price target on the stock.
Low
Report
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $14.00 price target on the stock.
11/18
11:34 am
ntla
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its "neutral" rating re-affirmed by analysts at William Blair. They now have a $14.00 price target on the stock.
Low
Report
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its "neutral" rating re-affirmed by analysts at William Blair. They now have a $14.00 price target on the stock.
11/18
10:31 am
ntla
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its price target raised by analysts at Chardan Capital from $88.00 to $91.00. They now have a "buy" rating on the stock.
Low
Report
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its price target raised by analysts at Chardan Capital from $88.00 to $91.00. They now have a "buy" rating on the stock.
11/18
08:22 am
ntla
ReCode Therapeutics Announces Additional Funding From the Cystic Fibrosis Foundation to Accelerate Development of Novel Gene Correction Therapeutics to Treat Cystic Fibrosis [Yahoo! Finance]
Medium
Report
ReCode Therapeutics Announces Additional Funding From the Cystic Fibrosis Foundation to Accelerate Development of Novel Gene Correction Therapeutics to Treat Cystic Fibrosis [Yahoo! Finance]
11/18
08:07 am
ntla
CF Foundation Invests Up to $15 million in ReCode Therapeutics to Develop a Gene Editing Therapy [Yahoo! Finance]
Low
Report
CF Foundation Invests Up to $15 million in ReCode Therapeutics to Develop a Gene Editing Therapy [Yahoo! Finance]
11/16
10:16 am
ntla
Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis
Low
Report
Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis
11/15
09:58 am
ntla
Cathie Wood says her ‘volatile' ARK Innovation fund shouldn't be a ‘huge slice of any portfolio' [CNBC]
Low
Report
Cathie Wood says her ‘volatile' ARK Innovation fund shouldn't be a ‘huge slice of any portfolio' [CNBC]
11/11
09:02 am
ntla
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $70.00 to $60.00. They now have an "outperform" rating on the stock.
Low
Report
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $70.00 to $60.00. They now have an "outperform" rating on the stock.
11/9
10:11 am
ntla
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Just Reported Third-Quarter Earnings And Analysts Are Lifting Their Estimates [Yahoo! Finance]
Medium
Report
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Just Reported Third-Quarter Earnings And Analysts Are Lifting Their Estimates [Yahoo! Finance]
11/8
11:07 pm
ntla
Intellia Therapeutics, Inc. (NASDAQ: NTLA) was upgraded by analysts at StockNews.com to a "sell" rating.
Medium
Report
Intellia Therapeutics, Inc. (NASDAQ: NTLA) was upgraded by analysts at StockNews.com to a "sell" rating.
11/8
01:44 pm
ntla
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its price target lowered by analysts at Barclays PLC from $76.00 to $55.00. They now have an "overweight" rating on the stock.
Low
Report
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its price target lowered by analysts at Barclays PLC from $76.00 to $55.00. They now have an "overweight" rating on the stock.
11/8
12:21 pm
ntla
Intellia Therapeutics Inc (NTLA) Q3 2024 Earnings Call Highlights: Financial Stability and ... [Yahoo! Finance]
Low
Report
Intellia Therapeutics Inc (NTLA) Q3 2024 Earnings Call Highlights: Financial Stability and ... [Yahoo! Finance]
11/7
07:30 am
ntla
Intellia Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress
Medium
Report
Intellia Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress
11/5
04:01 pm
ntla
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
10/31
07:30 am
ntla
Intellia Therapeutics Announces Two Upcoming Investor Events in November 2024
Low
Report
Intellia Therapeutics Announces Two Upcoming Investor Events in November 2024
10/25
05:36 pm
ntla
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its price target lowered by analysts at Citigroup Inc. from $25.00 to $19.00. They now have a "neutral" rating on the stock.
Low
Report
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its price target lowered by analysts at Citigroup Inc. from $25.00 to $19.00. They now have a "neutral" rating on the stock.
10/25
12:34 pm
ntla
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $31.00 to $20.00. They now have a "neutral" rating on the stock.
Low
Report
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $31.00 to $20.00. They now have a "neutral" rating on the stock.
10/25
08:37 am
ntla
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its price target lowered by analysts at Robert W. Baird from $24.00 to $18.00. They now have a "neutral" rating on the stock.
Low
Report
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its price target lowered by analysts at Robert W. Baird from $24.00 to $18.00. They now have a "neutral" rating on the stock.